Celltrion Inc

Overview

Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis, and psoriasis. Its pipeline portfolio spans monoclonal antibody biosimilars for the treatment of rheumatoid arthritis; colorectal cancer; and respiratory disease; and antibody biologics for and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer and seasonal influenza. Celltrion develops drugs by utilizing its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon, South Korea.
Key Stats
Address
23, Academy-ro, Yeonsu-gu, INCHEON, South Korea
Headquarters

South Korea

Contact

82 2 16618722

No of Employees

1,074

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

068270 [KOSE]

Revenue (2020)

$1,569 m

61.9% (2020 vs 2019)
Net Income (2020)

$434 m

69.9% (2020 vs 2019)
Net Profit Margin

28 %

4.9% (2020 vs 2019)
Market Cap *

$32,605 m

EPS *

$3.2

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Celltrion IncJW Pharmaceutical CorpSeoul Pharma Co LtdChoongAng Vaccine Laboratory
Key Information
Headquarters South Korea South Korea South Korea South Korea
Headquarter City INCHEON SEOUL CHEONGJU DAEJEON
Headquarter State/Province - - - -
No. of Employees 1,074 1,095 180 179
Entity Type Public Public Public Public

Products & Services

Celltrion is a pharmaceutical company. The company's major products, services and brands include the following:

Products
  • Remsima
  • Truxima
  • Herzuma
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Services
  • Contract Manufacturing:
  • API Biologics (Protein and Peptide)
  • Commercial Dose- Injectables
  • Etiam Rutrum Elit
  • Etiam Rutrum Elit
Brands
  • Remsima
  • Truxima
  • Herzuma
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In July, the company and Inhalon Biopharma Inc entered into a collaboration to develop IN-006,…
2021 Regulatory Approval In April, the company has received approval from US Food and Drug Administration (FDA) Emergency…
2021 Contracts/Agreements In August, the company and TriLink BioTechnologies entered into a partnership to develop a messenger…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Celltrion Pharm Inc

Address

82, 2sandan-ro, Ochang-eup, Cheongwon-gu, Cheongwon-gu, CHEONGJU
South Korea

Telephone

82 43 7177000

Website

www.celltrionph.com

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
22 Jul 2021 Inhalon Biopharma Enters into Partnership with Celltrion to Develop COVID-19 Treatment Partnership Celltrion Inc; Inhalon Biopharma Inc
07 Jun 2021 Iksuda Therapeutics Raises USD47 Million in Venture Financing Venture Financing Celltrion Inc; Mirae Asset Capital Co Ltd; Premier Partners LLC Iksuda Therapeutics Ltd
11 Feb 2021 Celltrion Enters Manufacturing Agreement with PCI Pharma Services for Yuflyma Contract Service Agreement Celltrion Inc PCI Pharma Services
20 Oct 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
20 Oct 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
20 Oct 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit